Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | CHKA | P35790 | 4/20 | 0.33 |
| ▸ | AHR | P35869 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 5/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410754 | 1.00 | CSNK2A2 (0.36) | CSNK2A2CSNK2BCSNK2A1TP53CHKA | |
| SCHEMBL30489827 | 0.77 | L3MBTL1 (0.38) | HSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL26607249 | 0.77 | VCAM1 (0.39) | — | |
| SCHEMBL2797388 | 0.77 | L3MBTL1 (0.38) | HSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL9796610 | 0.77 | ESR2 (0.41) | CHKAALDH1A1SMN1; SMN2 | |
| SCHEMBL26215514 | 0.76 | CSNK2A2 (0.39) | CSNK2A2CSNK2BCSNK2A1TP53CHKA | |
| SCHEMBL8754565 | 0.76 | CHKA (0.37) | CSNK2A2CSNK2BCSNK2A1TP53CHKA | |
| SCHEMBL2795974 | 0.75 | CYP2A6 (0.44) | TSHRLMNA | |
| Iodide SCHEMBL2551843 | 0.74 | CHKA (0.36) | CSNK2A2CSNK2BCSNK2A1TP53CHKA | |
| SCHEMBL11817663 | 0.74 | CSNK2A2 (0.36) | CSNK2A2CSNK2BCSNK2A1TP53AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042737-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12281078-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-10 | — | — | US | disclosed |
| US-12134609-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-12091387-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-03-21 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20240002346-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-01-04 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2007038865-A1 | SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA LTD. (CA) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007038865-A1 | SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA LTD. (CA) | 2007-04-12 | — | — | WO | disclosed |
| EP-1534681-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-6818772-B2 | DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS | ABBOTT LABORATORIES | 2004-11-16 | — | — | US | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004002960-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-08 | — | — | WO | disclosed |
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | ABBVIE INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003070244-A1 | ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-0027679-B1 | SUBSTITUTED-5-((7-CHLORO-4-QUINOLINYL)AMINO)-3-(AMINO-METHYL)-(1,1'-BIPHENYL)-2-OL COMPOUNDS; PROCESSES FOR THEIR PRODUCTION; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1983-08-10 | — | — | EP | disclosed |
| EP-0027679-A2 | Substituted-5-((7-chloro-4-quinolinyl)amino)-3-(amino-methyl)-(1,1'-biphenyl)-2-ol compounds; processes for their production; and pharmaceutical compositions containing the compounds | WARNER-LAMBERT COMPANY (US) | 1981-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002346-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | CSNK2A2 155/4885CSNK2B 143/4885CSNK2A1 205/4885 |
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | CSNK2A2 155/4885CSNK2B 143/4885CSNK2A1 205/4885 |
| US-12091387-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CSNK2A2 155/4885CSNK2B 143/4885CSNK2A1 205/4885 |
| US-20260042737-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, SSB, NT5C2 | CSNK2A2 424/4885CSNK2B 433/4885CSNK2A1 498/4885 |
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | CSNK2A2 155/4885CSNK2B 143/4885CSNK2A1 205/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CSNK2A2 155/4885CSNK2B 143/4885CSNK2A1 205/4885 |
| US-12134609-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CSNK2A2 155/4885CSNK2B 143/4885CSNK2A1 205/4885 |
| US-20030229119-A1 | Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor | MCHR1, MCHR2, MC1R | CSNK2A2 4120/4885CSNK2B 4012/4885CSNK2A1 4031/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | CSNK2A2 155/4885CSNK2B 143/4885CSNK2A1 205/4885 |
| US-12281078-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CSNK2A2 155/4885CSNK2B 143/4885CSNK2A1 205/4885 |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | CSNK2A2 2225/4885CSNK2B 1786/4885CSNK2A1 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.